Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 121

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 121
---
 during the three months ended September 30, 2024. For more information, see Note 8, Goodwill and Intangible Assets, to our condensed consolidated financial statements included herein.

On April 7, 2025, we, along with our operating subsidiary, Pacira Pharmaceuticals, Inc., entered into a settlement agreement with eVenus Pharmaceutical Laboratories, Inc.; their parent company—Jiangsu Hengrui Pharmaceuticals, Co. Ltd.; and Fresenius Kabi USA, LLC, with respect to this matter. For more information, see Note 16, Commitments and Contingencies, to our condensed consolidated financial statements included herein.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  49

Contingent Consideration Charges (Gains), Acquisition-related Expenses, Restructuring and Other

The following table provides a summary of the costs related to the contingent consideration charges (gains), acquisition-related expenses, restructuring and other during the periods indicated, including percent changes (dollar amounts in thousands): 

Three Months EndedSeptember 30,% Increase / (Decrease)Nine Months EndedSeptember 30,% Increase / (Decrease)2025202420252024Contingent consideration charges (gains)$625 $(3,244)N/A$(2,407)$(5,541)(57)%Restructuring charges3,728 1,193 100+%3,728 7,724 (52)%Acquisition-related expenses(280)285 N/A2,222 689 100+%Legal settlement— — N/A7,000 — N/ALegal judgment(23,148)— N/A(23,148)— N/AImpairment of acquired in-process research & development (IPR&D)25,866 — N/A25,866 — N/ATotal contingent consideration charges (gains), acquisition-related expenses, restructuring and other$6,791 $(1,766)N/A$13,261 $2,872 100+%

During the three and nine months ended September 30, 2025, total contingent consideration charges (gains), acquisition-related expenses, restructuring and other included net charges of $6.8 million and $13.3 million, respectively. During the three and nine months ended September 30, 2024, total contingent consideration charges (gains), acquisition-related expenses, restructuring and